Takeda tests new concentrated antibody shot against existing treatment
NCT ID NCT06895967
First seen May 13, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This completed Phase 1 trial enrolled 30 healthy adults aged 18-50 to compare how the body absorbs and clears two antibody treatments given as a single injection under the skin: TAK-881 and HyQvia. Participants stayed at the clinic for 8 days and had follow-up visits up to Day 85. The study focuses on drug levels in the blood, not on treating any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Celerion
Tempe, Arizona, 85283, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-881 (immune globulin with hyaluronidase) and HyQvia (immune globulin with hyaluronidase)
What this could lead to
If successful, this could help develop a more concentrated antibody treatment that is easier to inject under the skin.
What could go wrong
This is an early-phase trial in healthy volunteers, not patients. It only measures drug levels in the body, not whether the drug works for any disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.